OxyContin has always been the world's top-selling opioid painkiller and generated billions in sales for privately-held Purdue.
USA deaths linked to opioids have quadrupled since 2000 to roughly 42,000 in 2016, or about 115 lives lost per day.
The company's statement said it eliminated more than half its sales staff this week and will no longer send sales representatives to doctors' offices to discuss opioid drugs.
The maker of the powerful painkiller OxyContin said it will stop marketing opioid drugs to doctors.
Purdue and other opioid drugmakers and pharmaceutical distributors continue defending themselves against hundreds of local and state lawsuits seeking to hold the industry accountable for the drug overdose epidemic.
Doctors who want information on opioids will now need to contact the company's medical affairs department.
Purdue and other drugmakers have been fighting lawsuits by states, counties and cities that have accused them of pushing addictive painkillers through deceptive marketing.
The boom in OxyContin prescriptions, and the resulting expansion of the deadly abuse of opioids, has been consistently blamed on Purdue's aggressive and misleading marketing of the drug. Sales of OxyContin and other opioids have fallen recently amid pressure from regulators, insurers, and the general public.
Purdue's promotions exaggerated the drug's safety and risks of addiction, leading to lawsuits and federal investigations.
Purdue's decision to entirely stop marketing the drug in the USA comes amid a new wave of legal action, reminiscent of the legal campaign against tobacco companies in the 1990s.
Purdue has denied the allegations in the various lawsuits.
A surge in prescriptions of opioids followed the 1995 release of the drug when about 90 million opioid prescriptions were filled.
U.S. President Donald Trump has drawn criticism for his response to the opioid crisis.